17 OCTOBER 2018 |
||
SESSION I - COLORECTAL CANCER | CHAIRS: Şuayip Yalçın | |
13.30 - 14.00 | Is Shortening the Duration of Adjuvant Treatment is Eligible in Early Staged Colon Cancer? | Gökhan Demir |
14.00 - 14.30 | Is Tumor Sideness, Biomarkers or Molecular Subtype Classification More Predictive for the Treatment of Unresectable Metastatic Colon Cancer? | Şuayip Yalçın |
14.30 - 15.00 | Systemic Therapy for Potentially Resectable Metastatic Rectal Cancer | Ece Esin |
15.00 - 15.45 | Prolonging a Life is an Art, Paint with OPDIVO BMS Sattelite | CHAIRS: Berksoy Şahin SPEAKERS: Ahmet Gül, Berksoy Şahin |
SESSION II - NON-SMALL CELL LUNG CANCER | CHAIRS: Mustafa Erman | |
15.45 - 16.15 | Sequencing Agents in the Management of EGFR Mutation Positive Non-Small Cell Lung Cancer | Meral Günaldı |
16.15 - 16.45 | Management of ALK Non-Small Cell Lung Cancer Through First and Subsequent Lines of Therapy (Immunology Konusu) | Çiğdem Usul Afşar |
16.45 - 17.15 | Immunotherapy in Small and Non-small Cell Lung Cancer; The Role of Immune Checkpoint Inhibitors in Frontline and Beyond Frontline Therapy | Mustafa Erman |
17.15 - 17.45 | COFFEE BREAK | |
SESSION III - EARLY BREAST CANCER | CHAIRS: Erdem Göker | |
17.45 - 18.15 | Challenging Adjuvant Therapy in HER2+ Breast Cancer: Escalating or De-escalating ? | Gül Başaran |
18.15 - 18.45 | Evolving Approaches in Systemic Therapy for Triple-Negative Breast Cancer in Neoadjuvant and Adjuvant Settings | Özlem Er |
SESSION IV - URO-ONCOLOGY | CHAIRS: Sevil Bavbek | |
18.45 - 19.15 | What is the Role and Best Sequencing of the New Generation Hormonal Agents in the Treatment of Both Hormone Sensitive and Resistant Metastatic Prostate Cancer? | Mustafa Erman |
19.15 - 19.45 | How to Treat the Patients with Platin Ineligible Metastatic Bladder Cancer? | Nuri Karadurmuş |
19.45 - 20.15 | Perioperative Systemic Therapy for Localized Renal Cell Carcinoma: To Treat or Not to Treat | Sevil Bavbek |
18 OCTOBER 2018 |
||
SESSION V - MELANOMA | CHAIRS: İsmail Çelik | |
08.30 - 09.00 | Practice-Changing Developments in Stage III Melanoma: (neo-)Adjuvant Targeted Therapy and Immunotherapy | İsmail Çelik |
09.00 - 09.30 | Systemic Treatment of Stage IV Melanoma: Sequencing of Therapies, Biomarkers and the Cancer Immunogram | Bülent Orhan |
09.30 - 10.00 | Different Combinations of Systemic Therapy for Melanoma Brain Metastases | Burçak Karaca |
10.00 - 10.30 | COFFEE BREAK | |
SESSION VI - NON - COLORECTAL GIS TUMORS | CHAIRS: Gökhan Demir | |
10.30 - 11.00 | New (neo-)adjuvant Standarts of Care in Gastro-esophageal Cancer | Fatma Şen |
11.00 - 11.30 | What is Changed in the Treatment of Biliary Tract Cancer? | Tülay Akman Demir |
11.30 - 12.00 | Has Sorafenib Still Been the Real Winner Against New Generation TKIs and Immune Checkpoint Inhibitors in HCC? | Çagatay Arslan |
SESSION VII - ADVANCED / METASTATIC BREAST CANCER | CHAIRS: Berna Öksüzoğlu | |
12.00 - 12.30 | Optimizing Therapy for ER-Positive Metastatic Breast Cancer | Berna Bozkurt Duman |
12.30 - 13.00 | Overcoming Resistance in HER2+ Metastatic Breast Cancer | Berna Öksüzoğlu |
13.00 - 13.30 | Shining Side of the Moon; PARP Inhibitors in the Treatment of Advanced Triple Negative Breast Cancer | Ömer Dizdar |
13.30 - 14.30 | LUNCH BREAK | |
SESSION VIII - SARCOMA | CHAIRS: Berksoy Şahin | |
14.30 - 15.00 | Controversies in Adjuvant/Neoadjuvant Chemotherapy in Localized Soft Tissue Sarcoma | Sema Sezgin Göksu |
15.00 - 15.30 | Can We Ever Have a Specific Treatment for Every 50 Subtypes of Soft Tissue Sarcoma? | Berksoy Şahin |
15.30 - 16.00 | COFFEE BREAK | |
SESSION IX - HEAD AND NECK CANCER | CHAIRS: Musa Altun | |
16.00 - 16.30 | New Staging and New Treatments in Surgery for Head and Neck Cancer | H. Hakan Coşkun |
16.30 - 17.00 | Recent Advances in Nazofaranigal Carsinoma | Musa Altun |
17.00 - 17.30 | p16-Negative Advanced Head and Neck Cancer Treatment | Cemil Bilir |
19 OCTOBER 2018 |
||
SESSION X - IMMUNO-ONCOLOGY | CHAIRS: Jean-Francois Rossi | |
08.30 - 09.00 | Precision Immune Therapy For Cancers | Jean-Francois Rossi |
09.00 - 09.30 | Long-term Results of the Treatments with Immune Checkpoint Inhibitors in Solid Tumors | Oğuz Kara |
09.30 - 10.00 | CART Therapy for Solid Tumors | Xiao Yang |
10.00 - 10.30 | COFFEE BREAK | |
SESSION XI - PRECISION ONCOLOGY | CHAIRS: Fulden Yumuk | |
10.30 - 11.00 | The Bio-Informatics of Precision Cancer Medicine | Serdar Ceylaner |
11.00 - 11.30 | How Do Molecular Panels Help Me Make Clinical Decisions About My Patients? | Atıl Bişgin |
11.30 - 12.00 | Is Liquid Biopsy Success Story in the Manegenment of NSCLC ? | Fulden Yumuk |
12.00 | CLOSING | |